Patel Sanj K 4

What Happened

• Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals (KNSA), had multiple equity events dated April 1, 2026: conversions/exercises of derivative awards totaling 42,654 shares and new grants/awards of 210,300 restricted/performance units. To satisfy tax/exercise obligations, 10,313 shares were surrendered/disposed at $48.13 each for proceeds of $496,365 (transaction code F = payment of exercise price or tax liability).

Key Details

• Transaction date (all): April 1, 2026; Form 4 filed April 3, 2026 (appears timely).
• Derivative conversions/exercises (code M): total 42,654 shares (individual line items: 21,327; 6,481; 6,237; 8,609).
• Awards/grants (code A): RSUs/PSUs totaling 210,300 units (120,150; 60,100; 30,050) with $0 per-unit acquisition price.
• Tax withholding/payment (code F): 10,313 shares disposed at $48.13 = $496,365.
• Shares owned after transaction: not specified in the provided filing data.
• Notable footnotes:
  • RSUs: each RSU = contingent right to 1 Class A Ordinary Share (F1); RSU grants vest ratably over four years with 25% vesting on grant anniversaries (F3, F6–F8).
  • PSUs: each PSU converts to up to 200% of one share based on performance, with final conversion no later than Jan 30, 2029 (F4, F5).
  • Option vesting schedule (if applicable): 25% on first anniversary, then monthly over 36 months; vesting commencement date April 1, 2026 (F2).

Context

• The filing shows awards and derivative conversions alongside a share surrender to cover taxes/withholding — a routine administrative step (code F) rather than an open-market sale. Derivative entries (M) indicate exercises/conversions of vested awards; award entries (A) reflect new RSU/PSU grants. These items are common forms of executive compensation and do not necessarily indicate a change in the executive’s view of the company.